Literature DB >> 8289200

The structural basis of camptothecin interactions with human serum albumin: impact on drug stability.

T G Burke1, Z Mi.   

Abstract

The intense intrinsic fluorescence emissions from several clinically relevant camptothecin drugs have been exploited in order to study the structural basis of drug binding to human serum albumin. Both HPLC and time-resolved fluorescence spectroscopic methodologies were employed to characterize the associations of camptothecins with HSA in phosphate-buffered saline (pH 7.4) at 37 degrees C. The alpha-hydroxy delta-lactone ring moiety of camptothecin (C), 10-hydroxycamptothecin (HC), 10,11-(methylenedioxy)camptothecin (MC) and 9-chloro-10,11-(methylenedioxy)camptothecin (CMC) was in each case observed to hydrolyze more rapidly and completely in the presence of HSA than in the protein's absence. Binding isotherms constructed by the method of fluorescence lifetime titration showed that HSA bound preferentially the carboxylate forms of C, HC, MC, and CMC over their lactone forms, thereby providing an explanation for the shift to the right in the lactone-carboxylate equilibrium observed for each compound upon HSA addition. In marked contrast, three analogues (SN-38, CPT-11, and topotecan) all displayed enhanced stabilities in the presence of HSA. While the lifetimes of CPT-11, topotecan, and the carboxylate forms of both drugs were insensitive to the addition of HSA, the lifetimes of both SN-38 and its carboxylate form did titrate upon HSA addition. Analysis of binding isotherms constructed for the albumin interactions of SN-38 and its carboxylate form demonstrated a higher overall association constant for the lactone form [640 (M amino acid (aa) residues)-1] relative to the carboxylate form [150 (M aa)-1]. Our studies indicate that specific modifications at the 7- and 9-positions of the quinoline nucleus, such as those contained in CPT-11, topotecan, and SN-38, enhance drug stability in the presence of HSA. In the case of SN-38, the enhanced stability was shown to be due to preferential associations between the drug's lactone form and the blood protein.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8289200     DOI: 10.1021/jm00027a005

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  58 in total

1.  In vitro binding and partitioning of irinotecan (CPT-11) and its metabolite, SN-38, in human blood.

Authors:  O Combes; J Barré; J C Duché; L Vernillet; Y Archimbaud; M P Marietta; J P Tillement; S Urien
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

Review 2.  Clinical pharmacokinetics of irinotecan.

Authors:  G G Chabot
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

3.  Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model.

Authors:  Ryuta Saito; Michal T Krauze; Charles O Noble; Daryl C Drummond; Dmitri B Kirpotin; Mitchel S Berger; John W Park; Krystof S Bankiewicz
Journal:  Neuro Oncol       Date:  2006-05-24       Impact factor: 12.300

4.  Poisoning of mitochondrial topoisomerase I by lamellarin D.

Authors:  Salim Khiati; Yeonee Seol; Keli Agama; Ilaria Dalla Rosa; Surbhi Agrawal; Katherine Fesen; Hongliang Zhang; Keir C Neuman; Yves Pommier
Journal:  Mol Pharmacol       Date:  2014-06-02       Impact factor: 4.436

5.  NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma.

Authors:  Jenna H Burton; Christina Mazcko; Amy LeBlanc; Joseph M Covey; Jiuping Ji; Robert J Kinders; Ralph E Parchment; Chand Khanna; Melissa Paoloni; Sue Lana; Kristen Weishaar; Cheryl London; William Kisseberth; Erika Krick; David Vail; Michael Childress; Jeffrey N Bryan; Lisa Barber; E J Ehrhart; Michael Kent; Timothy Fan; Kelvin Kow; Nicole Northup; Heather Wilson-Robles; Joseph Tomaszewski; Julianne L Holleran; Miguel Muzzio; Julie Eiseman; Jan H Beumer; James H Doroshow; Yves Pommier
Journal:  Clin Cancer Res       Date:  2018-07-30       Impact factor: 12.531

6.  Rapid deconjugation of SN-38 glucuronide and adsorption of released free SN-38 by intestinal microorganisms in rat.

Authors:  Akira Takakura; Akinobu Kurita; Takashi Asahara; Masanori Yokoba; Michiko Yamamoto; Shinichiro Ryuge; Satoshi Igawa; Yukitoshi Yasuzawa; Jiichiro Sasaki; Hirosuke Kobayashi; Noriyuki Masuda
Journal:  Oncol Lett       Date:  2011-12-09       Impact factor: 2.967

7.  PEGylated nanographene oxide for delivery of water-insoluble cancer drugs.

Authors:  Zhuang Liu; Joshua T Robinson; Xiaoming Sun; Hongjie Dai
Journal:  J Am Chem Soc       Date:  2008-07-29       Impact factor: 15.419

8.  Anti-tumor activity of N-trimethyl chitosan-encapsulated camptothecin in a mouse melanoma model.

Authors:  Xian-Ping Liu; Sheng-Tao Zhou; Xing-Yi Li; Xian-Cheng Chen; Xia Zhao; Zhi-Yong Qian; Li-Na Zhou; Zhi-Yong Li; Yu-Mei Wang; Qian Zhong; Tao Yi; Zheng-Yu Li; Xiang He; Yu-Quan Wei
Journal:  J Exp Clin Cancer Res       Date:  2010-06-17

9.  Physicochemical characterization of 9-aminocamptothecin in aqueous solutions.

Authors:  Shahidur Rahman; Deval Patel; Michalakis Savva
Journal:  AAPS PharmSciTech       Date:  2013-12-03       Impact factor: 3.246

10.  Binding of PFOS to serum albumin and DNA: insight into the molecular toxicity of perfluorochemicals.

Authors:  Xian Zhang; Ling Chen; Xun-Chang Fei; Yin-Sheng Ma; Hong-Wen Gao
Journal:  BMC Mol Biol       Date:  2009-02-25       Impact factor: 2.946

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.